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Abstract
Nanomedicine is an emerging field that applies concepts in nanotechnology to the development of
novel diagnostics and therapeutics. Physical and chemical properties of particles, including size,
shape, modulus, surface charge and surface chemistry, play important roles in the efficacy of
nanomedicines. This review focuses on the effect of particle physical and chemical properties on
their interactions with cells in vitro and their pharmacokinetics and biodistribution in vivo.
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1. Introduction
Targeted drug delivery is one of the greatest challenges in medicine. Great strides have been
made in the design and implementation of drugs and drug carriers over the last 50 years.[1–4]
Nanomedicine, an emerging field that applies concepts in nanotechnology to the
development of novel diagnostics and therapeutics, is shifting the paradigm in drug delivery
of small molecule drugs and biologics.[1, 5, 6] Compared to small molecule therapeutics,
nanomedicines can enhance drug accumulation in the site of interest while averting many of
the side effects common to small molecule drugs. For example, small molecule anticancer
drugs are systemically distributed and preferentially kill rapidly proliferating cells (i.e.
cancer cells). There are significant side effects of these drugs, such as immunosuppression,
hair loss, nausea, and vomiting.[7–9] Nanoparticles can encapsulate or confine small
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molecule anti-cancer drug to avoid interaction with healthy cells and preferentially
accumulate in the tumor through the Enhanced Permeability and Retention (EPR) effect (c.f.
section 4.1).[5, 10] Furthermore, nanocarriers also play a vital role in the development of
macromolecular therapeutics, such as nucleic acids (e.g. siRNA, antisense RNA) and
proteins, that are difficult to deliver intracellularly.[11] Nanocarriers are also capable of
removing disease-related harmful materials like molecular sponges, such as low density
lipoproteins (LDLs) and cholesterols.[12, 13]
Researchers use a wide range of fabrication techniques in order to produce nanomedicines.
The two major nanofabrication techniques are bottom-up fabrication techniques and top-
down fabrication techniques. Bottom-up fabrication techniques involve self-assembly of
molecules and atoms to create particles, and top-down fabrication techniques generate
particles through the processing of bulk materials.[14] The self-assembly of amphiphlic
molecules forming liposomes, micelles, and polymersomes are examples of bottom-up
fabrication techniques.[15, 16] The self-assembled nature of these particles produces spherical
shapes and a large size distribution. Milling and grinding of bulk materials are examples of
top-down fabrication techniques. In order to produce shape-specific particles on the micron
and nanometer scales, a number of advanced top-down particle fabrication techniques have
been developed, such as hard template methods, microfluidics based methods, particle
stretching methods and photo- and e-beam lithography.[17] Recently, our group developed a
top-down fabrication technique termed Particle Replication In Non-wetting Templates
(PRINT®) technology, which enables independent control over particle size, shape,
modulus, surface chemistry, and composition (Figure 1). PRINT also provides a convenient
approach for systematically tailoring the chemical composition of nanoparticles without
changing the size, shape, and dynamics of the particle, a problem that often plagues many
other particle fabrication technologies, especially those derived from self-assembly
approaches when one adjusts the chemical composition.[17–28] A wide range of materials
can be used for PRINT particle fabrication, including biocompatible/biodegradable
polymers, inorganic materials, and biologics.
There are a number of excellent comprehensive reviews summarizing the many exciting
advancements in the nanomedicine field.[1, 19, 29–44] This review will focus on the effect of
particle physical and chemical properties on their interactions with cells in vitro and their
pharmacokinetics and dynamics in vivo. We will cover both nanoparticles and
microparticles, as microparticles also provide good insight into the development and
application of drug carriers.[45–50]
2. Cellular Entry Pathways for Particles
Particles and macromolecules can be taken up into cells through a process called
endocytosis.[51] There are two major mechanisms of endocytosis (Figure 2), which are
phagocytosis (cell eating, the uptake process of large particles) and pinocytosis (cell
drinking, the uptake process for small particles, fluid and solutes). Phagocytosis primarily
occurs in macrophages and polymorphonuclear neutrophils (PMNs). In contrast, pinocytosis
occurs in all types of cells through at least four distinct mechanisms: macropinocytosis,
clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis, and clathrin- and
caveolae independent endocytosis. All of these cellular entry processes are highly regulated
in order to precisely control cellular responses to the environment.[51]
2.1. Phagocytosis
Macrophages and PMNs are professional “eaters” that are capable of clearing foreign
materials, pathogens, including bacteria or yeasts, and cellular debris. A specific signaling
cascade triggers the assembly of actin, a globular 42-kDa protein, and the formation of cell-
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surface protrusions that engulf the foreign material or cellular debris.[52, 53] Macrophages
can engulf particles as large as 10 μm in diameter and are one of the major barriers that limit
the effective delivery of particles to the site of disease. In this review, we will mainly focus
on the detailed mechanisms of pinocytosis, which are more relevant to the cellular
internalization of nanomedicines.
2.2. Pinocytosis
Pinocytosis, or fluid-phase uptake, is the most common form of endocytosis and occurs in
all cell types.[51] Solutes can nonspecifically adsorb to the cell membrane to achieve
internalization (adsorptive pinocytosis). When solutes are captured by specific high-affinity
receptors, they can be internalized through a receptor mediated endocytosis (RME), which is
the most efficient pinocytic pathway. Overall, the pinocytotic pathway is determined by the
surface interaction of the particle and the cell.
2.2.1. Clathrin-mediated endocytosis (CME)—Clathrin-mediated endocytosis
requires the formation of coated pits by the assembly of clathrin, a protein that forms a
triskelion shape composed of three clathrin heavy chains and three light chains. Coated pits
develop into vesicles upon endocytosis. Two major examples of CME are the internalization
of cholesterol-rich low-density lipoprotein (LDL) particles through the LDL receptor and the
internalization of iron-loaded transferrin (Tf) through transferrin receptors (TfR). It is worth
noting that even though both LDL and Tf are internalized through CME, their intracellular
destinies are distinct; LDL is delivered to lysosomes for degradation, and Tf is recycled back
to the cell surface through a recycling mechanism. The final destination of an endocytic
vesicle is not only determined by the internalization mechanism but also by receptor
signaling. As such, the intracellular trafficking of nanoparticles conjugated with targeting
ligands will not always be the same as the trafficking pathway for the free ligand.[26, 54, 55]
Detailed examples will be discussed in the next section. Vesicles formed by CME have an
average size of 120 nm and are typically directed towards the lysosome for degradation of
their cargo.[51] Thus, for particles internalized by CME, endosomal escape is necessary for
successful delivery of macromolecules.
2.2.2. Caveolae-mediated endocytosis—Caveolae are small flask-shaped (50–60 nm)
invaginations of the plasma membrane on many cell types, particularly endothelial cells.[51]
The structure of caveolae is created by caveolin, a dimeric protein that binds cholesterol and
sphingolipids in certain areas of the cell membrane and leads to the formation of caveolae.
Simian virus 40 (SV40) particles are a good example of particles endocytosed through
caveolae-mediated endocytosis.[56] SV40 triggers its own uptake by multivalent crosslinking
of caveolae-localized surface receptors. Unlike the clathrin-mediated endocytosis, SV40
bypasses the endo-lysosomal compartments and is transported to the endoplasmic reticulum
and the nucleus. This caveolae-mediated pathway can be used for targeted macromolecule
delivery. The folic acid ligand has been proposed to be internalized through a caveolae-
mediated pathway.[34, 57–60] Albumin is internalized by interacting with endothelium gp60
receptors through a caveolae-mediated mechanism.[35] In general, caveolae-mediated
endocytosis is relatively slow (half-time, t1/2 > 20min) and the vesicles formed are small
(50–60 nm in diameter).[51]
2.2.3. Clathrin- and caveolin-independent endocytosis—Cellular entry can also
occur in cells without clathrin and caveolin. There are cholesterol-rich microdomains on the
plasma membrane referred to as lipid rafts (40 – 50 nm in length). For example, the
interleukin-2 (IL-2) receptor on lymphocytes is internalized in a clathrin- and caveolin-
independent manner.[61] These clathrin- and caveolin-independent pathways remain poorly
understood.
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2.2.4. Macropinocytosis—Macropinocytosis is a special clathrin- and caveolin-
independent endocytosis. Macropinocytosis is similar to phagocytosis as it is an actin-driven
process, but it is different from phagocytosis as the protrusions in macropinocytosis collapse
onto and fuse with the plasma membrane to generate large endocytic vesicles (0.5–10 μm).
Generally, macropinocytosis serve as a non-specific pathway to internalize large
particles.[30]
3. The impact of particle design on cellular internalization
The physical and chemical properties of particles play an important role in determining the
interactions with cells. We discuss how the particle size, shape, modulus, surface charge,
and surface chemistry determine the cellular entry mechanisms and intracellular trafficking
patterns.
3.1. Particle size
Particle size is a key factor in the process of particle internalization. A generally accepted
diameter of nanoparticles used to treat cancer is in the range of 10 – 100 nm, which is
determined by the in vivo clearance and distribution of nanoparticles (vide infra). Even
though small particles may facilitate the cellular entry process, there seems to be no size
limit up to 5 μm to gain cellular internalization.[21] Rejman et al. performed a systematic
study using different sizes (50 – 1000 nm) of polystyrene beads on a murine melanoma cell
line B16-F10.[62] It was reported that internalization of nanoparticles smaller than 200 nm
mainly involved in clathrin-mediated endocytosis. The authors also claimed that
nanoparticles with a diameter of 500 nm were internalized through the caveolae-mediated
pathway bypassing lysosomal accumulation. This caveolae-mediated endocytosis of the
particles contradicts the conventional notion that caveolae-mediated endocytosis is
associated with the internalization of small nanoparticles (~50 – 60 nm). The Hanes group
discovered that small polystyrene particles (< 25 nm) but not large particles (> 42 nm) can
enter HeLa cells via a cholesterol-independent, non-clathrin and non-caveolae mediated
pathway that avoids the endo/lysosomal accumulation.[63] Levy et al. reported that the
cellular internalization of 100 nm PLGA particles on a gastrointestinal epithelium cell line
(caco-2) is much faster than their 500 nm – 10 μm counterparts.[64] Chan et al. investigated
the interactions between a series of Herceptin® coated gold nanoparticles with well defined
sizes (2 – 100 nm) and a breast cancer cell line (SK-BR-3) and demonstrated that gold
nanoparticles with diameter of 40 and 50 nm can enter cells most effectively and improve
the therapeutic efficacy of Herceptin.[65, 66]
Taking advantage of the PRINT technology’s ability for precise control over particle size
and shape, our group studied the internalization of a series of polyethylene glycol hydrogels
(100 nm – 5 μm) on HeLa cells (Figure 3A).[21] A general trend found was that large
microparticles had slower internalization kinetics compared to small nanoparticles. The
internalization of these particles is through a combination of clathrin- and caveolae-mediated
pathways as well as non-clathrin- and non-caveolae-mediated pathways. In summary, the
rate and mechanism of cellular internalization of particles is size-dependent. For non-
phagocytic cells, nanoparticles tend to achieve faster cellular entry compared to
microparticles. Very small nanoparticles in the low tens of nanometer range may utilize a
non-clathrin- and non-caveolae-mediated pathway avoiding endo/lysosomal degradation,
which has significant implications for delivery of macromolecules.
3.2. Particle Shape
As the majority of particles used for drug delivery are fabricated using the bottom-up
fabrication strategy and tend to be spherical, there are a limited number studies evaluating
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the relationship between particle shape and cellular internalization. The Mitragotri group
fabricated a series of polystyrene particles with distinct size and shape by stretching methods
and discovered that particle shape, not size, plays a key role in macrophage
phagocytosis.[67–69] The tangent angles of the particle surface at the point making initial
contact with macrophages need to be smaller than 45° to allow for particle
internalization.[67] If the contact angle is larger than 45°, the cell can spread on the particle
surface but cannot internalize it. Taking advantage of these results, the same group
developed a shape-switching PLGA particle to control the particle phagocytosis by
macrophages.[70] Ferrari et al. predicted that prolate ellipsoids are the most effectively
attached to macrophages but are the least effectively internalized.[71] The groups of
Mitragotri and Smith used prolate ellipsoids, oblate ellipsoids and spheres to study their
particle shape interactions with macrophages and demonstrated Ferrari’s prediction
experimentally.[72]
Some very interesting observations have been made using PRINT particles by studying the
internalization of a series of polyethylene glycol based hydrogels (100 nm – 5 μm) on HeLa
cells (Figure 3A).[21] The internalization of the rod-like, high-aspect-ratio (AR)
nanoparticles (d = 150 nm, h = 450 nm, volume = 0.00795 μm3) occurs much more rapidly
and effectively than the cylindrical counterparts (d = 200 nm, h = 200 nm, volume =
0.00628 μm3), even though they have very similar volume, indicating the particle shape
plays a great role in the internalization process. To further elucidate the cellular
internalization mechanisms, the endocytosis of three types of particles, 150 nm (AR = 3),
200 nm (AR = 1), and 1 μm (AR = 1), was investigated using different biochemical
inhibitors of energy-dependent processes, clathrin-mediated endocytosis, caveolae-mediated
endocytosis, and macropinocytosis (Figure 3B). These particles were internalized through an
energy-dependent pathway based on a NaN3 inhibition experiment. In the presence of three
inhibitors for clathrin-mediated endocytosis, Dynasore, genistein, and chlorpromazine, both
150 nm and 200 nm particles showed markedly decrease in cell uptake; the internalization of
the 1 μm particles was only significantly affected by chlorpromazine. It is clear that the
nanoparticles, at least in part, enter cells through clathrin-mediated pathway. But the cell
entry mechanism cannot be delineated for 1 μm particles. In the presence of two inhibitors
for caveolae-mediated endocytosis, genistein, and β-cyclodextrin, the internalization was
retarded for the small nanoparticles but not the large microparticles. Since caveolae have a
cavity of ~60 nm, microparticle internalization through a caveolae-mediated pathway was
not expected. In addition, inhibition of >95% particle internalization was not found for any
inhibitor, indicating the possiblity for nonclathrin- and non-caveolae-mediated pathways for
internalization.
The Chan group reported that rod-like gold nanoparticles (14 × 40 nm and 14 × 74 nm)
entered cells less effectively compared to their spherical counterparts (74 nm in
diameter).[65] But it is worth noting that the surface of the gold nanorods was stabilized with
cetyl trimethylammonium bromide (CTAB), which is different from the citric acid-coated
spherical gold nanoparticles. The difference in surface chemistry may explain the disparity
in particle internalization.[65] In a follow-up study by the same group, transferrin-coated
gold nanorods was also internalized slower than transferrin-coated spherical gold
nanoparticles.[73] The studies by the DeSimone and Chan groups present contradictory
results. The studies of the impact of particle shape and cell interactions are still in their
infancy and more systems need to be explored.
3.3. Particle Modulus
The modulus of particles is another important parameter to induce or prevent particle
internalization.[40] Macrophages are trained to clear bacteria and other pathogens, which
usually have very rigid cell walls. Beningo and Wang reported that soft polyacrylamide
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beads (1 – 6 μm) frustrate the actin filament formation by macrophages and subsequently
prevent phagocytosis, whereas their stiff counterparts can be readily internalized.[74]
However, Lee et al. showed that rigid liposomes can decrease complement activation and
reduce subsequent macrophage uptake.[75] In a recent study by Merkel et al., very soft red
blood cell mimics can circulate several days, a 30-fold increase of elimination half-life
compared to their rigid counterparts.[28] But both the soft and rigid particles showed very
minimal uptake on human umbilical vein endothelial cells (HUVEC), probably due to their
large sizes. No conclusive relationship has emerged between the particle modulus and
cellular internalization process.
3.4. Particle Surface Charge
In general, nanoparticles with positively charged surfaces can be effectively internalized by
cells through electro-static interactions with the negatively charged cell plasma membrane
(adsorptive endocytosis, possibly involving CME). There are numerous examples of
positively charged particles for cellular internalization, such as PLL modified PLGA,
chitosan, searylamine-coated PEG-co-PLA etc.[38, 76, 77] The DeSimone group has also
reported that by keeping the size and shape of particles constant, positively charged
nanoparticles were internalized in 84% of cells after 1-hr incubation, whereas the negatively
charged counterparts were not internalized (< 5%).[21]
On the other hand, negatively charged nanoparticles, such as DOXIL® and micelles are
more likely to take advantage of caveolae-mediated pathways.[78] It also has been reported
that negatively charged PLGA nanoparticles (~100 nm) can enter cells through caveolae-
independent pathways.[79–81] The Mirkin group successfully demonstrated the use of 13 nm
gold nanoparticles for gene delivery.[82–84] The gold nanoparticles were negatively charged,
but they were effectively internalized and delivered the nucleic acids to the cytosol and
nucleus.
3.5. Particle Surface Chemistry
Surface modification of particles is an area of intense investigation for tissue and cell-
specific delivery. A number of targeting strategies and surface chemistry have been
developed.[41] A general targeting strategy takes advantage of the over-expression of certain
cell surface receptors. Nanoparticles conjugated with molecules that can specifically bind to
the receptors are expected to boost the particle avidity (i.e. multivalent affinity) to cells.
Transferrin receptors are overexpressed on the majority of cancer cells and are widely used
as a cancer cell target.[85] Transferrin and transferrin receptor antibodies have also been used
for site-specific drug delivery for various systems, including protein/toxin conjugates,
polymer/drug conjugates, modified viral vectors, liposomes/polyplexes, and
nanoparticles.[5, 86, 87] Two types of liposomal formulations for targeted drug/gene delivery,
MBP-426 and SGT-53 that are currently under phase I clinical trials, utilize transferrin and
an anti-transferrin receptor single-chain antibody fragment as targeting moieties,
respectively.[5] The Davis group developed the most successful targeted delivery system to
date for small interfering RNA (siRNA), transferrin-conjugated cyclodextrin polymer-based
NPs (CALAA-01), that is undergoing a phase I clinical trial.[11, 88–93] FDA approved
monoclonal antibodies have also been used as targeting ligands, such as Herceptin® and
Rituxan®.[66, 94, 95] The Schnitzer group reported that aminopeptidase P antibody conjugated
gold nanoparticles can be transported into endothelium cells through a caveolae mediate
mechanism.[35, 96–99] Small peptides have also been explored as targeting ligands, such as
the RGD peptide.[100, 101] Aptamers, single-strand short nucleic acids, are a class of new
targeting ligands, which can bind any target, including proteins and small molecules, with
very high affinity.[102–104] The Langer and Farokhzad groups developed nanoparticle-
aptamer bioconjugates for cancer targeting.[105–110] Small molecule ligands can also be used
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as targeting moieties. Pioneered by the Low group, folic acid has been widely used as a
targeting ligand for drug conjugates, liposomes and nanoparticles.[34] Sigma receptors (σ1,
σ2) have been targeted by Huang and colleagues using anisamide as a high-affinity sigma-
receptor ligand.[111–118] Liposomes conjugated with anisamide can substantially improve
the delivery of chemotherapeutics and siRNA to tumors. Mukherjee et al. reported that
haloperidol, another sigma-receptor ligand, can increase DNA delivery efficiency by 10-fold
to breast carcinoma cells.[119]
Not only boosting avidity to cells, multivalent ligands on nanoparticles can also have an
impact on cell biology that cannot be achieved by the monovalent form of
ligands.[26, 66, 120–122] Our group recently discovered that multivalent presentation of
transferrin, the fourth most abundant serum protein in humans, on nanoparticles can
transform this benign protein into a potential “drug-free” chemotherapy against a B-cell
lymphoma.[26] Kopecek et al. also took advantage of the multivalent ligands to crosslink
CD20 receptors to induce apoptosis in B cells.[123] Multivalent presentation of certain
monoclonal antibodies on nanoparticles has been reported to enhance the therapeutic
efficacy of the antibody.[66, 95] Tan et al. fabricated dinitrophenyl conjugated gold
nanoparticles with well-controlled ligand density and showed that these multivalent
nanoparticles can regulate signaling in mast cells as a function of particle size and surface
ligand density.[116] Multivalent nanoparticles can also inhibit HIV fusion to human T cells
and kill multidrug resistant bacteria, where the monovalent ligands did not show any
biological activity.[121, 122]
It is worth noting that the cellular trafficking mechanisms for multivalent ligand conjugated
nanoparticles may be different from the monovalent ligand. Endothelial cells express
intercellular adhesion molecule 1 (ICAM-1) but do not internalize ICAM-1 antibodies.
However, anti-ICAM-1 antibody-coated nanoparticles can be readily taken up by endothelial
cells through a unique cell adhesion molecule (CAM)-mediated endocytosis, which is
different from clathrin-, caveolae-, macropinocytosis- and phagocytosis-mediated
pathways.[124] Mukherjee et al. also demonstrated that upon multivalent presentation on
nanoparticles, the patterning and dynamics of anti-EGFR (epidermal growth factor receptor)
antibody cetuximab is distinct from its monovalent form.[125] Iversen et al. showed that
transferrin conjugated quantum dots were internalized through clathrin-mediated
endocytosis, but the exocytosis pathway of free transferrin was blocked.[55]
4. The impact of particle design on biodistribution and pharmacokinetics
The size, shape, modulus, and surface chemistry of particles also play an important role in
the biodistribution and pharmacokinetics. Fundamental in vivo studies regarding particle
design enable the engineering of better medicines for the treatment of a variety of diseases.
There remains much to be elucidated, but the impact of particle design has proven to be
important for drug delivery.
4.1. Particle Size
Particle size is an important component in the design of long-circulating particle systems. As
discussed previously, the generally accepted diameter of nanomedicine for cancer is in the
range of 10 – 100 nm. The lower limit is determined by the sieving coefficients for the
glomerular capillary wall in the kidney to avoid renal filtration.[126] Particles of sizes
ranging from 10 nm to 15 μm have different pharmacokinetic parameters and
biodistribution. Under normal homeostatic conditions, large particles are mechanically
filtered through the spleen and liver by the reticuloendothelial system (RES). The RES, one
of the body’s defense and filtration mechanisms, functions to remove old or irregular red
and white blood cells, as well as opsonized constituents and large foreign objects.
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Fenestrations in the spleen are typically 200 – 500 nm in width, and thus, particles larger
than 200 nm must compensate by deformability.[42] For certain diseases, such as cancer, size
of particles can play a large role in accumulation of the particles for therapeutic and
diagnostic purposes. Solid tumors typically present with aberrant angiogenic vasculature that
enables passive accumulation of particles. In a human colon adenocarcinoma xenograft
model, the cutoff size of the vascular pores was determined to be 400 – 600 nm in
diameter.[127] Characteristic solid tumors have higher interstitial pressure in the center of the
tumor compared to the periphery. An outward convective flow reduces drug diffusion to the
center of the tumor, and particles and drugs that gain interstitial access have higher retention
times than in normal tissues. This aberrant vasculature and higher interstitial fluid pressure
create an enhanced permeability and retention of the nanoparticles. Particles that are smaller
than the fenestration can gain access and be retained in the tumor.[41, 42, 128]
4.2. Particle Shape
The importance of particle shape has derived the morphological adaptation of pathogens in
nature. The shape of the pathogen serves a critical biological function, where infectious and
metastatic agents with different shapes, sizes, and moduli can cope with and adapt to
external conditions. Examples in nature are influenza, ebola, and filoviruses — these are
viruses with morphologies that have been subject to the selective forces of survival and
proliferation.[129] Exploiting the self-assembly characteristics of symmetric amphiphiles,
Geng et al. created worm-like particles, termed filomicelles, and evaluated their circulation
times in vivo and anti-cancer efficacy (Figure 4).[130] The filomicelles were created from
one of two materials, PEG:polyethylethylene (inert) and PEG:polycaprolactone
(biodegradable). The pharmacokinetics of the filomicelles was evaluated using fluorescence
imaging of a hydrophobic dye that was retained within the particles. The particles were
shown to circulate for up to one week in rodents, and the circulation time of the filomicelles
show a dependence upon length of the particle. PEGylated ‘stealth’ vesicles were also
evaluated and found to be cleared within two days. Particles of an initial length of 8 μm
persist longest in circulation; however, particles longer than 8 μm underwent rapid chain
scission.
Paclitaxel-loaded filomicelles were evaluated as a cancer therapy.[130] Tumor-bearing nude
mice (A549 subcutaneous xenograft tumors) were administered 1 μm or 8 μm particles via
intravenous injection. The results seven days post-injection showed that filomicelles
provided an advantage as a drug carrier compared to the controls of free drug. An eight-fold
increase in the length of the filomicelle was equivalent to an eight-fold increase in drug
administration. The 1 μm or 8 μm particles provided similar reductions in tumor burden and
a doubling of the apoptosis after one week.
Furthermore, the circulation times and endothelial cell targeting of intravenously injected
ICAM-1-targeted elliptical disks (0.1 × 1 × 3 μm) and ICAM-1-targeted spheres (0.1, 1, 5,
and 10 μm) were evaluated in C57Bl/6 mice.[54] The 0.1 μm ICAM-1-targeted spheres were
rapidly cleared from the blood post-injected, with 16.2 ± 2.7% of the injected dose (%ID)
and 5.2 ± 0.5% ID remaining in the blood 1 minute and 30 minutes post-injection,
respectively. Hepatic uptake of these carriers was substantial at 43.7 ± 4.5% of the ID per
gram of organ tissue. Pulmonary uptake was significant compared to the non-targeted
control spheres, showing 114.7 ± 11.1 % ID/g versus 10.2 ± 3.9% ID/g, respectively. The
larger ICAM-1-targeted spheres were cleared faster than the 0.1 μm ICAM-1-targeted
spheres. The ICAM-1-targeted elliptical disks remained in circulation longer than the
spheres, with 25.5 ± 2.8 %ID and 20.9 ± 1.6% ID remained in the blood at 1 and 30 minutes
post-injection, respectively. There was much lower hepatic uptake (15.7 ± 2.3% ID/g) and
significant pulmonary uptake (186.2 ± 15.4% ID/g). Thus, the elliptical disks showed
greater pulmonary targeting compared to spherical particles.[54]
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A difference between the moduli of metastatic cancer cells and non-metastatic cancer cells
has been discovered, and this difference in modulus has been thought to be a major
mechanism enabling these cells to relocate and take hold in other parts of the body.[131, 132]
Modulus was evaluated using red blood cell mimic (RBCM) hydroxyethyl acrylate (HEA)
hydrogel PRINT® particles.[28] The RBCMs were negatively charged, micron-sized,
biconcave disks that were the same size as mouse red blood cells (6 μm) and were used to
evaluate the influence of modulus on circulation times (Figure 5A). Tensile testing of
macroscopic coupons of these hydrogels was performed at varying percentages of the
crosslinker, poly(ethylene glycol diacrylate) (PEGDA) (neutral pH), resulting in a modulus
ranging from 63.9 ± 15.7 to 7.8 ± 10.0 kPa (Figure 5B). A reduction in the cross-linking
density exhibited modulus values within the range of red blood cells (26 ± 7 kPa). Scaled-
down master templates were fabricated to allow the RBCMs to swell to the desired
dimensions upon hydration, yielding discs that were 5.2–5.9 μm in diameter and 1.22–1.54
μm tall, with the feature size and final RBCM dimensions dependent upon the percent of
cross-linker. The filling of the molds resulted in a meniscal effect, yielding RBCMs that
were similar to the biconcave shape of red blood cells (Figure 5A). A near IR dye
(Dylight680 maleimide) was used for in vivo imaging in mice.
The RBCMs were initially evaluated using microfluidic models of vascular constriction. The
more deformable (1 and 2% crosslinked) RBCMs were found to be able to navigate 3 μm
wide and 50 μm long channels (Figure 5D), while the more rigid (5 and 10% crosslinked)
RBCMs clogged the channels (Figure 5C). The more deformable RBCMs retained their
shape after distorting many times, reverting back to their original shape once flow was
halted. Intravital microscopy was used to evaluate the microcirculation of the intravenously
injected RBCMs. For in vivo studies, the peripheral vasculature of an anesthetized mouse’s
ear was observed, and the near-IR fluorescence of the particles was evaluated over a two-
hour time course wherein elimination curves were generated. The most rigid RBCMs were
cleared quite rapidly, while the most deformable RBCMs were eliminated over 30 times
more slowly. The most deformable RBCMs were also monitored using the more traditional
blood-draw method. The pharmacokinetic analysis of this data was consistent with the data
obtained using the intravital microscope, showing an elimination half-life of 3.8 days with
5% of the injected dose remaining in the blood after 5 days.[133]
Evaluation of the biodistribution of the RBCMs after two hours post-injection revealed large
lung accumulation for the most rigid particles (Figure 6), which is typical for intravenously-
injected microparticles. The bulk of the dose was sequestered through the first pass. The
stiffer RBCMs were poorly tolerated while the more flexible RBCMs were well tolerated
due to the avoidance of filtration in the lung. The more flexible RBCMs were largely
sequestered into spleen. Lung filtration was avoided by particles with 2% or less cross-
linker, and kidney filtration was significant for all but 1% of the crosslinked RBCMs.[133]
Thus, modulus was found to play an important role in particle pharmacokinetics and
biodistribution.
4.4 Particle Surface Charge
Surface charge plays a significant role in nonspecific cellular internalization and protein
absorption in circulation. Particles with a positively charged surface are expected to have
high nonspecific internalization rate and short blood circulation half-life. It has been found
that polystyrene microparticles with primary amine surface functionalities undergo
substantially more phagocytosis compared to the same particles with carboxyl, sulfate, and
hydroxyl groups.[134] Yamamoto et al. evaluated surface charge on poly(ethylene glycol)-
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poly(D, L-lactide) block copolymer micelles using neutral (tyrosine) and negative (tyrosine-
glutamine) functionalities. No difference was found between blood clearance kinetics, but
the negatively-charged micelles displayed a 10x lower accumulation in liver and spleen four
hours post-intravenous administration.[135] He et al. evaluated negatively charged
(rhodamine B labeled carboxymethyl chitosan grafted) nanoparticles and positively charged
(chitosan hydrochloride grafted nanoparticles) for cellular uptake and biodistribution.[136]
Particles with a surface charge below 15 mV showed a reduction in phagocytic uptake by
murine macrophages, and the particles with lower surface charges promoted longer blood
residence time and higher accumulation in the tumors of subcutaneous xenograft H-22
tumor-bearing mice.
4.5. Particle Surface Chemistry
The surface properties of a particle can affect its interactions with molecules, cells, or
physiological systems in the body and impart a variety of desirable characteristics for the
delivery of therapeutics and diagnostics. For example, the chemical conjugation of PEG
groups onto the surface of particles has enabled stealth-like properties when in circulation.
The PEG groups have the ability to reduce non-specific uptake by cells, to diminish
adsorption by proteins and other biomolecules in the serum, and to elude phagocytosis by
macrophages, all of which contribute to longer circulation time.[137] Another desirable
characteristic for particles in biomedical applications is the ability to selectively interact
with specific cell types such as cancer cells. This selectivity can ensure that an effective
amount of the therapeutic payload will be delivered to the target cells of interest, thereby
minimizing the potential side effects that accompany intravenous chemotherapy. Li and
Huang have proposed that ideal particle delivery systems transport to the target site at > 10%
injected dose in 4 hours and are cleared from circulation between 4 and 10 hours for safety.
PEG density plays an important role, and for the treatment of cancer, it has been proposed
that high density and sheddable PEG chains are the key for tumor targeting.[128]
Surface modification with targeting moieties is advantageous for cellular endocytosis after
particle accumulation in the site of interest. Weissleder et al. used a combinatorial approach
to find targeting moieties for cells of interest. This approach involved the creation of 146
iron oxide nanoparticles decorated with different synthetic small molecules.[138] The library
created was tested for specificity for endothelial cells (HUVEC), activated human
macrophages (U937), and pancreatic cancer cells (PaCa-2), and small molecules were
delineated for their specificity to each system. Fourteen candidates showed significant
uptake in the pancreatic cancer cells, and from these fourteen, two candidates exhibited high
pancreatic cancer cell uptake and low macrophage/endothelial cell uptake. The two
candidates were isatoic anhydride (designated 261-15-28) and 5-chloro-isatoic anhydride
(261-14-17). Fluorescently labeled candidates (CLIO-isatoic-Cy5.5) were intravenously
injected into subcutaneous xenograft mice and were compared with a control group CLIO-
NH2-Cy3.5 using fluorescence imaging (TBR of 1.62 versus 0.16, p value < 0.0001). The
results proved an increase in pancreatic cancer detection in the mouse model using the
targeting moiety.[138]
5. Conclusions
In summary, the following physical parameters for effective nanomedicines are
recommended:
• Size: Particles in the range of 10–100 nm can avoid renal filtration and are small
enough to efficiently accumulate in tumors through the EPR effect. However,
microparticles may be better suited for vascular targeting than nanoparticles.
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• Shape: Certain shape specific delivery systems have demonstrated advantages over
spherical systems. Filamentous particles can help evade macrophage uptake, and
shape-specific microparticles can enhance vascular adhesion.
• Modulus: Soft particles can navigate through pores smaller than the size of
particles and achieve extended circulation.
• Surface charge and surface chemistry: Neutral PEGylated particles are ideal to
avoid macrophage uptake. Introducing targeting ligands can also potentially
enhance cancer cell uptake.
Future studies in this field should focus on creating more effective nanomedicines by
designing particles to target certain organs, control particle intracellular trafficking pathways
and deliver cargo to intracellular organelles.
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